Secukinumab (Cosentyx) — intravenous (Medicare Advantage)
Customize your policy alerts
Sign up for blue cross blue shield - louisiana Policy MA-223 alerts
Get alerted when Policy MA-223 changes without checking for updates manually.
Monitor payer policy activity
Medicare Advantage medical policy governing coverage criteria for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis for members of the Health Plan.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.